

APPLICANTS: Crossman *et al.*
FILING DATE: April 12, 2004
FOR: DIAGNOSTICS AND THERAPEUTICS FOR RESTENOSIS

In the claims:

1.-7. (Cancelled)

8. (Original) A kit for determining the existence of or a susceptibility to developing a restenosis in a subject, said kit comprising a first primer oligonucleotide that hybridizes 5' or 3' to an allele selected from the group consisting of allele 1 of any of the following markers: IL-1A (+4845), IL-1B (-511), IL-1B (+3954), IL-1RN (VNTR) and IL-1RN (+2018) or an allele in linkage disequilibrium therewith.

9. (Currently Amended) A The kit of claim 8, which additionally comprises a second primer oligonucleotide that hybridizes either 3' or 5' respectively to the allele so that the allele can be amplified.

10. (Currently Amended) A The kit of claim 9, wherein said first primer and said second primer hybridize to a region in the range of between about 50 and about 1000 base pairs.

11. (Currently Amended) A The kit of claim 8, wherein said primer is selected from the group consisting of any of SEQ ID Nos. 1-14.

12. (Currently Amended) A The kit of claim 8, which additionally comprises a detection means.

13. (Currently Amended) A The kit of claim 12, wherein the detection means is selected from the group consisting of:

- a) allele specific oligonucleotide hybridization;
- b) size analysis;
- c) sequencing;
- d) hybridization;
- e) 5' nuclease digestion;

APPLICANTS: Crossman *et al.*
FILING DATE: April 12, 2004
FOR: DIAGNOSTICS AND THERAPEUTICS FOR RESTENOSIS

- f) single-stranded conformation polymorphism;
- g) allele specific hybridization;
- h) primer specific extension; and
- j) oligonucleotide ligation assay.

14. (Currently Amended) A The kit of claim 8, which additionally comprises an amplification means.

15. (Currently Amended) A The kit of claim 8, which further comprises a control.

16.-79. (Cancelled)